miReculeā„¢ is an early-stage biotechnology company developing RNA-based therapeutics. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. miRecule’s DREAmiRā„¢ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease and then create an RNA therapeutic that can directly target and fix that genetic abnormality. miRecule is applying this platform to a variety of diseases, including cancer and muscular dystrophy.